Drug Use Investigation for XYZAL®

This post-marketing surveillance study (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rhinitis, Allergic, Perennial and Seasonal Infections Nose Diseases Otorhinolaryngologic Diseases Respiratory Tract Diseases Respiratory Tract Infections Rhinitis

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must be the first time for taking levocetirizine tablet

Exclusion criteria

As this is PMS study, there are no exclusion criteria.

Treatment and study plan

Levocetirizine

Drug

Primary outcomes

The number of adverse events in Japanese subjects treated with levocetirizine tablets

Time frame: 4 weeks

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Drug Use Investigation for XYZAL

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2013
First posted: Oct 3, 2011
Registry last updated: Aug 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed